This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Eaton Corporation: Portfolio Transformation and The Cost of Capital (Abridged)
Esty, Benjamin C.; Mayfield, E. Scott; Fisher, DanielCase HBS-221070-EFinanceIn 2000, Eaton Corporation was a broadly diversified industrial conglomerate. But its strategy was evolving and its focus was narrowing around "power management" and more recently on "intelligent power," the use of digitally enabled products and services designed to enhance efficiency and reliability. To implement this transition, Eaton had acquired more than 70 companies and divested another 50. Such active portfolio management required Eaton to...Starting at €8.20
-
United Technologies: Are the Parts Worth More Than the Whole
Esty, Benjamin C.; Fisher, DanielCase HBS-220018-EFinanceAfter spending more than 50 years creating a diversified industrial conglomerate that Fortune Magazine described as "arguably the most profitable conglomerate in America" in 2014, UTC's CEO Greg Hayes was under pressure from activist investors (Dan Loeb aStarting at €8.20
-
Impax Laboratories: Executing Accretive Acquisitions (B)
Esty, Benjamin C.; Fisher, DanielCase HBS-220031-EFinanceIExplores events after Impax announced the acquisition of a portfolio of generic pharmaceutical products from Teva in June 2016.Starting at €5.74
-
Impax Laboratories: Executing Accretive Acquisitions (A)
Esty, Benjamin C.; Fisher, DanielCase HBS-220030-EFinanceImpax Laboratories was a technology-based pharmaceutical company that used a "dual platform" strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the early morning of June 21, 2016, the firm issued a press release announcing it was buying a portfolio of generic drugs from Teva for $586 million in cash. The leadership team (CEO, CF...Starting at €8.20